Pennsylvania Trust Company raised its position in shares of Pfizer Inc. (NYSE:PFE) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 467,214 shares of the biopharmaceutical company’s stock after buying an additional 2,446 shares during the period. Pfizer makes up about 1.3% of Pennsylvania Trust Company’s investment portfolio, making the stock its 22nd largest position. Pennsylvania Trust Company’s holdings in Pfizer were worth $15,082,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Lowe FS increased its position in Pfizer by 54.9% in the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock worth $23,000 after buying an additional 260 shares during the last quarter. Taylor Wealth Management Partners boosted its stake in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 105 shares during the period. Lincoln Capital boosted its stake in shares of Pfizer by 5.7% in the fourth quarter. Lincoln Capital now owns 8,316 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 446 shares during the period. Vicus Capital boosted its stake in shares of Pfizer by 17.6% in the fourth quarter. Vicus Capital now owns 8,547 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 1,282 shares during the period. Finally, First Hawaiian Bank boosted its stake in shares of Pfizer by 4.9% in the fourth quarter. First Hawaiian Bank now owns 9,140 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 429 shares during the period.

Pfizer Inc. (NYSE:PFE) opened at 30.71 on Monday. Pfizer Inc. has a 1-year low of $28.47 and a 1-year high of $36.46. The stock has a market capitalization of $189.57 billion and a P/E ratio of 23.06. The company has a 50-day moving average price of $31.87 and a 200 day moving average price of $33.24.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.09. The company earned $12.10 billion during the quarter, compared to analyst estimates of $11.56 billion. The business’s revenue was down 2.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.57 earnings per share. On average, equities analysts predict that Pfizer Inc. will post $2.18 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 2nd. Shareholders of record on Friday, February 5th will be paid a $0.30 dividend. The ex-dividend date is Wednesday, February 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.91%. This is a positive change from Pfizer’s previous quarterly dividend of $0.24.

A number of brokerages recently issued reports on PFE. JPMorgan Chase & Co. upped their target price on Pfizer from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Monday, November 2nd. Cowen and Company upped their target price on Pfizer from $34.00 to $35.00 and gave the company a “market perform” rating in a research report on Monday, November 2nd. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Independent Research GmbH reissued a “neutral” rating and issued a $38.00 target price on shares of Pfizer in a research report on Wednesday, October 28th. Finally, Deutsche Bank upped their target price on Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Six research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.